Thiacetazone has been used as an antitubercular agent since the 1960s. Reportedly, thiacetazone is a prodrug that is oxidatively converted to their active forms by the flavin monooxygenase EtaA of
Mycobacterium tuberculosis. Thiacetazone is bacteriostatic in action against tuberculosis through the inhibition of mycolic acid biosynthesis. Because the activity of thiacetazone is weak, it is usually used as a combination with first-line tuberculosis medications, such as isoniazid [
I0138] and rifampicin [
R0079]. (The product is for research purpose only.)